BREAKING: Stock Market Hits Record Highs After Cool CPI After peaking in February 2021, biotech stocks as a group didn't participate once the market turned around after 2022. This summer seems to have changed that. Biotech stocks are not easy to handle individually. The development stage cohort is filled with stocks that have no earnings and often no revenue, except for inconsistent milestone payments. That just happens to be the majority of members in the nearly 800 stock Medical-Biomed/Biotech group. But ...

Core Viewpoint - Geron Corporation (NASDAQ: GERN) has experienced a potential plateau in the sales of its product Rytelo (imetelstat) shortly after its launch in mid-2025, which may be causing market concerns [1] Company Summary - Geron Corporation has only reported two full quarters of sales for Rytelo since its introduction [1] - The market appears to be reacting to the stagnation in sales growth following the product's launch [1]